羟基脲治疗危重婴儿恶性百日咳
该前瞻性病例系列在法国一家转诊PICU开展,纳入2017年1月至2024年7月因重症百日咳收治的危重婴儿27例,其中12例表现为恶性百日咳,7例接受羟基脲、5例接受全血置换(BE)。羟基脲剂量为20 mg/kg/d,中位疗程12天,高白细胞增多在7天内成功下降。12例中总死亡3例(25%),所有患儿均需呼吸支持,8例有创机械通气、3例接受体外膜氧合。作者认为羟基脲是恶性百日咳感染的一种替代治疗,能有效处理高白细胞增多且死亡率有限。
要点
- 12例恶性百日咳婴儿中7例用羟基脲、5例用全血置换(BE),总死亡3/12(25%)。
- 羟基脲剂量20 mg/kg/d,中位疗程12天,高白细胞增多在7天内成功下降。
- 所有患儿均需呼吸支持,8例有创机械通气、3例接受体外膜氧合。
- 多数患儿为足月儿且小于3个月龄。
- 作者认为羟基脲是恶性百日咳的替代治疗,可有效处理高白细胞增多且死亡率有限。
适用人群与场景
- 法国一家转诊PICU收治的危重婴儿(n=27),为重症百日咳感染,研究期间2017年1月至2024年7月。
- 其中12例表现为恶性百日咳(多器官衰竭、高白细胞增多);多数为足月儿且小于3个月龄。
处置流程与药物剂量
- 羟基脲给药剂量为20 mg/kg/d,中位疗程12天,用于恶性百日咳婴儿以降低白细胞。
- 全血置换(BE)作为另一干预措施用于恶性百日咳婴儿。
- 所有患儿均接受呼吸支持,其中8例有创机械通气、3例接受体外膜氧合治疗。
研究设计与关键结果
- 前瞻性病例系列,法国一家转诊PICU,纳入2017年1月至2024年7月重症百日咳危重婴儿27例,其中12例为恶性百日咳。
- 12例恶性百日咳中7例接受羟基脲、5例接受全血置换(BE);主要终点为28天生存,次要终点为羟基脲降低血白细胞计数的疗效。
- 总死亡3/12(25%);羟基脲20 mg/kg/d、中位12天,高白细胞增多在7天内成功下降。
- 所有患儿均需呼吸支持,8例有创机械通气、3例接受体外膜氧合。
证据类型、等级与局限
- 证据类型:前瞻性病例系列。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,羟基脲是恶性百日咳感染的一种替代治疗,能有效处理高白细胞增多且死亡率有限。
- 原文报告羟基脲20 mg/kg/d、中位12天可使高白细胞增多在7天内成功下降,并以此作为全血置换(BE)的替代选择。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Malignant pertussis, the most severe manifestation of Bordetella pertussis infection, is characterized by multiple organ failure and a high mortality rate despite advanced intensive care measures. Hyperleukocytosis is the hallmark of malignant pertussis and necessitates urgent and aggressive interventions. Among the therapeutic options, leukoreduction via whole blood exchange (BE) transfusion has been associated with significant procedural risks and potential clinical deterioration. Hydroxyurea was recently proposed as a pharmacological alternative for leukoreduction. This study reports our clinical experience with hydroxyurea as an alternative to BE in managing infants with malignant pertussis admitted to a PICU.
DESIGN: Prospective case series.
SETTING: A referral PICU in France.
PATIENTS: Critically ill infants (n = 27) with severe pertussis infection.
INTERVENTIONS: Hydroxyurea therapy or BE transfusion.
MEASUREMENTS AND MAIN RESULTS: We reviewed all critically ill infants admitted to our unit for severe pertussis between January 2017 and July 2024. The primary outcome was 28-day survival, and the secondary outcome was the efficacy of hydroxyurea on blood leukocyte count reduction. Among the 27 infants admitted for severe pertussis, 12 exhibited features of malignant pertussis. Of these, seven were treated with hydroxyurea and five with BE. The majority of infants were term and under 3 months old. All patients required ventilatory support, with eight on invasive mechanical ventilation and three receiving extracorporeal membrane oxygenation therapy. Overall mortality was three of 12 (25%). Hydroxyurea was administered at a dose of 20 mg/kg/d for a median duration of 12 days. Hyperleukocytosis was successfully reduced within 7 days.
CONCLUSIONS: Hydroxyurea is an alternative therapy for malignant pertussis infection that can efficiently address hyperleukocytosis with limited mortality.
参考来源
- Blanc M, Marais C, Debs A, et al. Hydroxyurea for Malignant Pertussis in Critically Ill Children. Crit Care Explor. 2025. PMID: 39937591. doi:10.1097/CCE.0000000000001218
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。